The P-CDM was also investigated for adjuvant conjugation, and the coadministration of P-CDM-OVA and the P-CDM-adjuvant conjugate NPs further improved CTL responses in vivo and effectively reduced tumor growth in mice. Thus, the CDM linked polymer presents a promising platform for anticancer immunotherapy.Psoriatic skin lesions are metabolically active, which makes them candidates for imaging with 18-F fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT). The aim of our study was to correlate FDG-PET findings with Psoriasis Area and Severity Index (PASI) scores, the most widely-used grading system for psoriasis. Thirty-three subjects and a total of 84 FDG-PET/CT scans from a prospective clinical trial [NCT01553058] with >2 months moderate-to-severe psoriasis were included. Subjects underwent whole-body FDG-PET/CT imaging 60 min after intravenous FDG administration, prior to the start of treatment. Scans were repeated 12 weeks and 52 weeks after baseline scans were conducted and after treatment or placebo administration was initiated. Each subject and scan was graded by our "PET-PASI" scoring system, a qualitative review of multi-plane reconstructions for both attenuation-corrected (AC) and non-attenuation-corrected (NAC) PET images. PASI and PET-PASI scores were correlated using Spearman's rho analysis. Our study demonstrated a significant positive correlation between each subject's corresponding PET-PASI and PASI scores before and during treatment or placebo administration (r=0.53, P less then 0.001). We also found positive correlations between PET-PASI and PASI scores across different regions of the body (head and neck r=0.22, upper extremities r=0.26, trunk r=0.48, and lower extremities r=0.58). In conclusion, AC and NAC FDG-PET/CT images may be utilized to evaluate lesions in subjects with moderate-to-severe psoriasis. Our methodology could have future implications in the diagnosis and therapeutic management of psoriasis.The practical application of dual-time-point-imaging (DTPI) technique still remains controversial. One of the issues is that current parameters of DTPI quantification suffer from some deficiencies, mainly limited sampling of the diseased sites by confining measurements to specific locations. We aimed to examine the correlation between the percent change from early to delayed scans in whole-bone marrow (WBM) 18F-FDG uptake, as measured by a CT-based method of PET/CT quantification, and response to treatment in multiple myeloma (MM) patients. Pre-treatment 18F-FDG-PET/CT scans of 36 newly diagnosed MM patients were collected in a prospective study at 1 h and 3 h post tracer injection (NCT02187731). PF6463922 A threshold algorithm based on bone Hounsfield units on CT was applied to segment and quantify WBM 18F-FDG uptake. Patients were separated into two treatment groups high-dose therapy with autologous stem cell transplant (HDT) and non-high dose therapy (non-HDT). The International Response Criteria for MM patients was used to determine each patient's response to treatment. In the HDT group, WBM 18F-FDG uptake increased significantly in patients that had a poor response to treatment, from a median of 1.31 (IQR 1.13-1.64) at 1 h to a median of 1.85 (1.45-2.10) at 3 h. The median percent change was 37.77% (IQR 23.47-46.4), with a range of 6.10-50.73 (P = 0.003). However, no significant change in uptake was observed in patients with a complete response (P = 0.24). The same trend was observed for the non-HDT group. WBM uptake of 18F-FDG assessed with dual-time-point imaging may have a role in predicting treatment response in MM.MAG3 scintigraphy with determination of split renal function (SRF) is a standard procedure in patients with metastasized castration-resistant prostate carcinoma (mCRPC) undergoing PSMA radioligand therapy (PSMA-RLT). These patients also receive frequent PSMA PET/CT scans for staging and follow up. PSMA is not only overexpressed in prostate cancer epithelial cells, but also physiologically overexpressed in the proximal tubular cells of the kidney. This study investigates the utility of PSMA-targeted imaging for determination of relative renal function. mCRPC patients (n = 97) having received 68Ga-PSMA-11 PET/CT and 99mTc-MAG3 scintigraphy in close temporal relationship were included in this retrospective study. PSMA-PET-derived SRF was calculated according to the bilateral renal PSMA content (total kidney PSMA = SUVmean × volume), MAG3-based SRF (SRFMAG3) using the common standard integral method of the renal secretion phase. The agreement of SRFPSMA and SRFMAG3 was statistically tested using Pearson correlation and Bland-Altman analysis. The correlation between both SRF assessment methods was highly significant (P less then 0.001) with r=0.91. Bland-Altman analysis confirmed agreement of the measurements. High correlation and agreement were also observed in the subgroup analyses of patients with normal and reduced renal function (r=0.81, P less then 0.001 and r=0.98, P less then 0.001). Renal tubular PSMA expression allows assessment of split renal function by 68Ga-PSMA-11 PET/CT imaging. Additional MAG3 scintigraphy for the purpose of quantifying relative renal function contribution may be spared in settings where PSMA PET is performed; this insight could save time and unnecessary examinations.We determined the optimal imaging time for axillary lymph node (LN) visualization following Tc-99m Tilmanocept in breast cancer patients to establish imaging guidelines that can allow for a reliable and efficient yet high yield study prior to surgery. Retrospective analysis in 651 patients who underwent lymphoscintigraphy, comparing LN visualization on immediate, 15-minute, and 90-minute delayed imaging after injection of Tc-99m Tilmanocept. Statistical analysis was performed using McNemar's test, kappa coefficient, and Pearson Chi-square test. Five hundred and six patients had either immediate or immediate and 90-minute delayed imaging. Of these patients, 203 (40.1%) had both immediate and 90-minute delayed images. Of these 203 patients, 54 (26.6%) had ≥1 lymph node(s) identified immediately and 196 (96.6%) had ≥1 lymph node(s) identified at 90 minutes (P less then 0.0001). A kappa coefficient of .0256 was observed (95% CI .0058-.0453). One hundred and forty-five additional patients had 15-minute delayed imaging.